CHO-NECTIN4 Cells

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entities the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please contact us.CHO-NECTIN4 cells are a stable recombinant Chinese hamster ovary (CHO) cell line engineered to express human Nectin-4 (also known as PVRL4 or Poliovirus receptor-related protein 4), a type I transmembrane protein belonging to the nectin family of cell adhesion molecules. Nectin-4 is a well-established tumor-associated antigen that is overexpressed in multiple solid tumor types, including urothelial bladder carcinoma, breast cancer, non-small cell lung cancer, and pancreatic cancer, making it a clinically validated target for antibody-drug conjugates (ADCs) and other targeted immunotherapeutics. The ADC enfortumab vedotin, which targets Nectin-4, is approved for treatment of urothelial carcinoma, underscoring the therapeutic relevance of this antigen.CHO-NECTIN4 cells are widely used for the development and characterization of Nectin-4-directed antibodies, ADCs, bispecific antibodies, and CAR-T cell therapies. The stable recombinant expression system supports quantitative binding assays, ADCC/CDC cytotoxicity evaluations, receptor internalization studies, and high-throughput antibody screening by flow cytometry. The CHO background provides low endogenous expression of most human surface antigens, ensuring that observed signals are attributable to the stably expressed Nectin-4 transgene. This cell line is validated for use in drug discovery workflows, preclinical candidate selection, and mechanistic studies of Nectin-4 receptor biology.